Axela, Inc. Launches dotLab(TM) System in Europe.Novel System Advances Capabilities for Protein Research TORONTO -- Axela Inc., a recognized innovator in protein interaction technology, announced the introduction of the dotLab[TM] System in Europe at Analytica 2008, being held in Munich, Germany, April 1-4, 2008. The system, successfully introduced in North America North America, third largest continent (1990 est. pop. 365,000,000), c.9,400,000 sq mi (24,346,000 sq km), the northern of the two continents of the Western Hemisphere. in 2007, is now being used by life scientists in the academic, pharmaceutical, biotechnology and clinical research fields to exploit interactions between a protein target and other biomolecules This page aims to list articles on Wikipedia that describe particular biomolecules or types of biomolecules. This list is not necessarily complete or up to date - if you see an article that should be here but isn't (or one that shouldn't be here but is), please update the page . Chosen by Frost and Sullivan as the Protein Assay Product of the Year for 2007, the dotLab System brings real-time monitoring to the study of protein interactions, expression, immunoassay Immunoassay An assay that quantifies antigen or antibody by immunochemical means. The antigen can be a relatively simple substance such as a drug, or a complex one such as a protein or a virus. development, and routine quantitation. This eliminates the time and cost of platform transitions associated with conventional approaches. The presentation at Analytica, Understanding Interactions Enables Real-Time Immunoassays, will be given by Paul Smith, VP Research Markets in the Innovations and Technology Forum on April 3, 2008, Hall A3, 384/I, 13:00 - 13:30. The dotLab system will be on display in Hall A3, Booth 276. "We are excited to have achieved this milestone in Axela's corporate growth," says Rocky Ganske, Axela President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "Existing users quickly demonstrated how understanding interactions can improve protein detection and quantitation. Simultaneously measuring low and high abundance proteins and interrogating complexes directly in biological samples enables significant new applications." Axela's European Sales and Support Office will be located in Bemmel, The Netherlands and managed by TouchDown Biomarketing B.V. This highly experienced team provides local scientific and technical support and is backed by extensive consumable A material that is used up and needs continuous replenishment, such as paper and toner. "The low-tech end of the high-tech field!" and reagent reagent /re·a·gent/ (re-a´jent) a substance used to produce a chemical reaction so as to detect, measure, produce, etc., other substances. re·a·gent n. distribution capability. About Axela, Inc. Axela has developed a proprietary technology for real-time protein detection, characterization A rather long and fancy word for analyzing a system or process and measuring its "characteristics." For example, a Web characterization would yield the number of current sites on the Web, types of sites, annual growth, etc. , and monitoring directly in biological samples. The company's products provide simple tools and reagents to life science and clinical researchers to study interactions, expand the utility of traditional immunoassays and access novel categories of diagnostic markers. Participating in the research market provides unique access to novel discoveries that form the basis of a growing content pipeline for future multiplex See multiplexing. diagnostic offerings. Axela is a privately-held company with operations in Toronto and California whose major investor is VenGrowth Private Equity Partners Inc., one of Canada's premier private equity managers. (c) 2008 Axela, Inc. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion